FAS Reduced the Cost of Schizophrenia Drug by Almost 12.5%

12:30; 24 November 2025 year

The Federal Antimonopoly Service (FAS) has approved a price reduction for a drug used in the treatment of schizophrenia and type I bipolar disorder. The price of "Lurazidon Krono" has been reduced by 12.49%. This reduction was made in relation to the registered prices of the foreign reference drug "Latuda". As a result, the price for 28 tablets of the generic drug in a dosage of 20 mg is now 1,660 rubles, while the cost of the same package of the reference drug is 1,898 rubles. According to the antitrust service, the approval of prices for the domestic generic will make drugs more affordable and expand the range of available options after the patent on the original expires. In medical organizations across the country, it is provided free of charge under the state guarantees program.

Investment

Events

Niches and markets

Technologies and trends

Development infrastructure